Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity —Reply

In Reply The authors raise 5 issues related to our trial of tirzepatide. First, the glucagon-like peptide-1 (GLP-1) receptor agonist class has been available for the treatment of type 2 diabetes since 2005 and for the treatment of obesity since 2014, and has been the subject of increasing worldwide use. Although nausea, diarrhea, constipation, and vomiting are the most common adverse effects of this class of medication, appropriate clinical treatment of patients can reduce these common adverse effects and increase tolerability. Such treatment includes slow titration or downtitration of the medication or symptomatic management of the adverse effects. Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist, has been studied for chronic weight management in 4 global phase 3 trials and is now approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity. Similar to the class of GLP-1 receptor agonists, it has been found to be safe and effective when used as intended.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research